Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No directors can buy shares if they 're expecting material news within the next 30 days, which has certainly been Huw's position since becoming CEO in October. DYOR
Big news could land here at anytime, and those that have sold their shares cheaply and those that haven't taken advantage of this rockbottom sp because they've been told a placing is coming...ha ha ha...are going to regret their decisions imho...Gla holders....no other Bio around that offers so much Transformational upside potential from such a low market cap. :-)
I disagree good company directors buy shares to show shareholders there on the right path ...Graham mullis ...Novacyt ....trial results brazil keep me intrested here ...
Good post king.
Huw's proably been an insider since day 1 and therefore unable to buy any shares even if he wanted, personally i don't give a jot if he does or doesn't and i'm only interested in the delivery of material events on the pipeline.......news of which could drop at anytime.....and no doubt within 30 days of the last update. Gla ;-)
ps and with enough cash until "the tail end of this year" according to Huw's recent statement....no fund raise required either, unless Evgen's business model has been radically changed. Gla Holders ;-)
..............................
This guide is based on UK law as at 1st February 2010, unless otherwise stated. It is part of a series on the FSA and Securities Regulation.
In order to reduce the risk that directors and senior managers of quoted companies might be thought to be taking advantage of inside information (see: Insider dealing, an OUT-LAW guide), both the Listing Rules and the rules of AIM require that companies restrict the times at which their directors and senior managers can deal in the company’s shares. In the case of fully listed companies, the Listing Rules contain a ‘Model Code’ on share dealing by directors and senior employees that companies are required to adopt in full (though they may impose more onerous restrictions if they want).
Like the rules for disclosures in relation to shares (see: Disclosures in relation to shares, an OUT-LAW guide), the Code applies to both directors and other PDMRs and defines ‘dealing’ widely. If there is any doubt as to what is caught, seek advice.
Directors and other PDMRs must not deal in shares during a ‘close period’, that is the period of 60 days before the announcement of annual results or the publication of the annual report (or, if shorter, the period from the end of the financial year to the announcement or publication). In the case of half-year results, it is the time between the end of the half year and the date of publication. If a company reports quarterly, the close period is 30 days before each announcement or, if shorter, the period between the end of the quarter and publication. (The same restriction does not apply to the company’s interim management statement, though a cautious approach would impose a similar 30-day ban on dealing.)
This is a simple prohibition: it is taken as read that, during those periods when financial results are being prepared, senior personnel are likely to have price-sensitive information.
Outside those periods, directors and other PDMRs are still prohibited from dealing if there is undisclosed inside information. (See: Disclosure of price-senstive information, an OUT-LAW guide.) This might be news of a possible takeover, a significant share issue or a big contract win or loss.
0
He's been inside since day one, and so probably no window for the foreseeable with so much going on, anyways he was given a shed load of shares when he was appointed CEO and so lots of incentive to deliver shareholder value.....and plenty more news to look forward to in the coming weeks and months for Huw to realise that incentive. ...good news drop at anytime!!! Gl a:)
Past and present senior management are more then happy talking up this company but rarely dip into their own pocket to back up their excitement.
Stephen Franklin only ever purchased £12460 worth of shares using his own funds, and Barry Clare even less at £8900.
As far as I can see the current incumbent hasn't even bothered.
Admittedly they do recieve share options but if they really believe in their product surely they'd be backing it with their own funds. I think we are being played here.
Munch, what happened you only posted 7 times today ?
Frustrating share to hold this. Persons unknown seem willing to keep selling at low prices, but nobody ever comes up with a reason on here or the other site why you would sell at this valuation.
Yes in the recent interview Huw said they would update the market when the 100 was reached and remind the market about the DSMB assessment (including hopefully an expected timescale) at that point.
That's correct Ontarget, 6 trial sites originally and 10 trial sites according to the recruitment protocol, and Prof Chalmers also put an invitation out last week out for more potential trial sites to get in touch if interested. Tayside clinical unit also describes the recruitment now as Rapid , 58 patients recruited by 19th January from 9 that was confirmed 10th December, and so that equates to more than 50 a month, and so given the surging numbers of hospitalised patients, the recruitment of the first 100 patients to SFX-01 could be approaching fast....along with the Data and Safety Monitoring Board's assessment on the first 100 patients, Huw also confirmed that he will update the market on safety and if it's working and expects the trial to continue to Top line data, expected July...obviously the green light from the DSMB will be a huge endorsement and any positive detail from Huw could see a massive re-rate with any luck.....news of which could arrive much sooner than Finncap's April suggestion. Gl :-)
Tayside Clinical Trials Unit Retweeted
James D Chalmers
@ProfJDChalmers
·
Latest from the STAR-COVID trial announced today.
Rapid enrolment past 50 patients randomized.
Thanks @TASC_TCTU
@EvgenPharma
and funders @lifearc1
STAR-COVID is testing whether SFX-01 will improve outcomes in hospitalized patients with suspected COVID19
htTps://star-covid19.com
https://twitter.com/tasc_tctu?lang=en
What makes you say it's being done at a single site Mumbo_Jumbo? Didn't the previous RNS mention multiple sites?
The issue is the time taking to getting enough people on the trial. I presume it’s being done at a single site in Dundee, which is a small city. They should have got other Scottish hospitals involved especially from Glasgow and Edinburgh.
There is lot of promise here but it’s taking an eternity to get the recruitment done. With lockdown measures bringing the infection rate down, the recruitment process will slow along with it. They should look into getting the trial started at multiple sites.